Copyright ©2014 Baishideng Publishing Group Inc.
World J Hepatol. Oct 27, 2014; 6(10): 759-765
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.759
Figure 3
Figure 3 Odds/probabilities of a sustained virological response with regard to interleukin 28B-genotype in different protease inhibitor based triple therapy. The differences between the shown estimates correspond to the odds ratios. A greater difference of odds between the both IL-28B-genotype corresponds to a more beneficial effect. SVR: Sustained virological response; IL-28B: Interleukin 28B.